Adenomyosis

Last updated
Adenomyosis
Adenomyosis.jpg
Adenomyosis uteri seen during laparoscopy: soft and enlarged uterus; the blue spots represent subserous endometriosis.
Specialty Gynecology
Frequency20 to 35%. [1]

Adenomyosis is a medical condition characterized by the growth of cells that proliferate on the inside of the uterus (endometrium) atypically located among the cells of the uterine wall (myometrium), [2] as a result, thickening of the uterus occurs. As well as being misplaced in patients with this condition, endometrial tissue is completely functional. The tissue thickens, sheds and bleeds during every menstrual cycle. [2]

Contents

The condition is typically found in women between the ages of 35 and 50, but also affects younger women. [3] Patients with adenomyosis often present with painful menses (dysmenorrhea), profuse menses (menorrhagia), or both. Other possible symptoms are pain during sexual intercourse, chronic pelvic pain and irritation of the urinary bladder.

In adenomyosis, basal endometrium penetrates into hyperplastic myometrial fibers. Unlike the functional layer, the basal layer does not undergo typical cyclic changes with the menstrual cycle. [4] [5] Adenomyosis may involve the uterus focally, creating an adenomyoma. With diffuse involvement, the uterus becomes bulky and heavier. [6]

Adenomyosis can be found together with endometriosis; it differs in that patients with endometriosis present endometrial-like tissue located entirely outside the uterus. In endometriosis, the tissue is similar to, but not the same as, the endometrium. The two conditions are found together in many cases yet often occur separately. [7] [4] Before being recognized as a distinct condition, adenomyosis was called endometriosis interna. The less-commonly-used term adenomyometritis is a more specific name for the condition, specifying involvement of the uterus. [8] [9]

Signs and symptoms

Adenomyosis can vary widely in the type and severity of symptoms that it causes, ranging from being entirely asymptomatic 33% of the time to being a severe and debilitating condition in some cases. Women with adenomyosis typically first report symptoms when they are between 40 and 50, but symptoms can occur in younger women. [3] [6]

Symptoms (viz., heavy bleeding and pain) and the estimated percent affected may include: [6]

Clinical signs of adenomyosis may include:

Women with adenomyosis are also more likely to have other uterine conditions, including:

Causes

The cause of adenomyosis is unknown, although it has been associated with any sort of uterine trauma that may break the barrier between the endometrium and myometrium, known as the junctional zone, such as a caesarean section, surgical pregnancy termination, and any pregnancy. It can be linked with endometriosis, [12] but studies looking into similarities and differences between these two conditions have conflicting results. [13]

The pathogenesis of adenomyosis still remains unclear, but the functioning of the inner myometrium, also called the junction zone (JZ), is believed to play a major role in the development of adenomyosis. It is also a matter of discussion whether the link between reproductive disorders and major obstetrical disorders also lies here. [14] Parity, age, and previous uterine abrasion increase the risk of adenomyosis. Hormonal factors such as local hyperestrogenism and elevated levels of s-prolactin as well as autoimmune factors have also been identified as possible risk factors. [15] [16] [17] As both the myometrium and stroma in an adenomyosis affected uterus show significant differences from those of a non-affected uterus, a complex origin that includes multifactorial changes on both genetic and biochemical levels is likely. [18] [19]

The tissue injury and repair (TIAR) theory is now widely accepted and suggests that uterine hyperperistalsis (i.e., increased peristalsis), during early periods of reproductive life will induce micro-injury at the endometrial-myometrial interface (EMI) region. [20] That again leads to elevation of local estrogen in order to heal the damage. At the same time, estrogen treatment will increase uterine peristalsis again, leading to a vicious circle and a chain of biological alterations essential for the development of adenomyosis. Iatrogenic injury of the junctional zone or physical damage due to placental implantation most likely results in the same pathological cascade. [21]

Mechanism

Pathophysiology

Cross section through the wall of a hysterectomy specimen of a 30-year-old woman who reported chronic pelvic pain and abnormal uterine bleeding. The endometrial surface is at the top of the image, and the serosa is at the bottom. Adenomyosis, Hysterectomy Specimen.jpg
Cross section through the wall of a hysterectomy specimen of a 30-year-old woman who reported chronic pelvic pain and abnormal uterine bleeding. The endometrial surface is at the top of the image, and the serosa is at the bottom.

Misplaced endometrial tissue proliferation in the myometrium causes symptoms through different mechanisms. [6]

Uterine menstrual contractions are caused by prostaglandin, which is produced by normal endometrial tissue. [6] Dysmenorrhea is the main characteristic for this disease which are the result for high prostaglandin levels. Endometrial proliferation is also led by estrogen; some treatments try to reduce its levels in order to decrease symptoms. [6] Adenomyosis patients present with heavy menstrual bleeding due to the increase of endometrial tissue, greater degree of vascularization, atypical uterine contractions and increased levels of prostaglandins, estrogen and eicosanoids. [22]

Histopathology

The diagnosis of adenomyosis is through a pathologist microscopically examining small tissue samples of the uterus. [4] These tissue samples can come from a uterine biopsy or directly following a hysterectomy. Uterine biopsies can be obtained by either a laparoscopic procedure through the abdomen or hysteroscopy through the vagina and cervix. [6]

The diagnosis is established when the pathologist finds invading clusters of endometrial tissue within the myometrium. Several diagnostic criterion can be used, but typically they require either the endometrial tissue to have invaded greater than 2% of the myometrium, or a minimum invasion depth between 2.5 and 8mm. [6]

Histopathological image of uterine adenomyosis observed in hysterectomy specimen. Hematoxylin & eosin stain. Uterine adenomyosis (1).JPG
Histopathological image of uterine adenomyosis observed in hysterectomy specimen. Hematoxylin & eosin stain.

Gross Findings:

  1. Enlarged uterus
  2. Thickened uterine wall with trabeculated appearance
  3. Hemorrhagic pinpoint or cystic spaces throughout wall [23]

Microscopic Findings:

  1. Endometrial glands and stroma haphazardly distributed throughout myometrium
  2. Concentric myometrial hyperplasia frequent around adenomyotic foci
  3. Variants: Gland-poor, stroma-poor, intravascular [23]

Differential Diagnosis:

  1. Adenomyoma
  2. Myo-invasive endometrial endometrioid carcinoma (vs. stroma-poor adenomyosis)
  3. Low-grade endometrial stromal sarcoma (vs. gland-poor and intravascular adenomyosis) [23]

Diagnosis

Imaging

Adenomyosis can vary widely in the extent and location of its invasion within the uterus. As a result, there are no established pathognomonic features to allow for a definitive diagnosis of adenomyosis through non-invasive imaging. Nevertheless, non-invasive imaging techniques such as transvaginal ultrasonography (TVUS) and magnetic resonance imaging (MRI) can both be used to strongly suggest the diagnosis of adenomyosis, guide treatment options, and monitor response to treatment. [6] Indeed, TVUS and MRI are the only two practical means available to establish a pre-surgical diagnosis. [24]

Transvaginal ultrasonography

Transvaginal ultrasound of the uterus, showing the endometrium as a hyperechoic (brighter) area in the middle, with linear striations extending upwards from it Linear striations of adenomyosis.jpg
Transvaginal ultrasound of the uterus, showing the endometrium as a hyperechoic (brighter) area in the middle, with linear striations extending upwards from it

Transvaginal ultrasonography is a cheap and readily available imaging test that is typically used early during the evaluation of gynecologic symptoms. [24] Ultrasound imaging, like MRI, does not use radiation and is safe for examination of the pelvis and female reproductive organs. [25] Overall, it is estimated that transvaginal ultrasonography has a sensitivity of 79% and specificity of 85% for the detection of adenomyosis. [11]

Common transvaginal ultrasound findings are defined by the European MUSA group in 2015 [26] and are defined in 2022 by the MUSA group. [27] The ultrasound characteristics can be divided in direct and indirect features.

Direct features:

  • myometrial cysts - pockets of fluid within the smooth muscle of the uterus
  • Hyperechogenic islands - usually white endometrium islands within the myometrium
  • Echogenenic subendometrial lines and buds - usually white lines and knobs attached to the endometrium, prtruding into the myometrium.

Indirect features:

  • Globular, enlarged, and/or asymmetric uterus
  • Fan shaped shadowing - differentiating from fibroids with linear shadowing
  • Anterior/posterior wall asymmetry
  • Translational vascularity - diffuse spread of small vessels within the myometrium
  • Irregular or interrupted junctional zone - the borderline between the endometrium and myometrium

The power Doppler or Doppler ultrasonography function can be used during transvaginal ultrasonography to help differentiate adenomyomas from uterine fibroids. [24] [28] [29] This is because uterine fibroids typically have blood vessels circling the fibroid's capsule. In contrast, adenomyomas are characterized by widespread blood vessels within the lesion. [24] Doppler ultrasonography also serves to differentiate the static fluid within myometrial cysts from flowing blood within vessels. [24]

The junction zone (JZ), or a small distinct hormone-dependent region at the endometrial-myometrial interface, may be assessed by three-dimensional transvaginal ultrasound (3D TVUS) and MRI. Features of adenomyosis are disruption, thickening, enlargement or invasion of the junctional zone. [21] There is no consensus about the actual histology of the junctional zone and a recent review showed that the ultrasound, MRI and histology all define and describe the junctional zone differently. [30]

Sagittal MRI of a woman's pelvis showing a uterus with adenomyosis in the posterior wall. Gross enlargement of the posterior wall is noted, with many foci of hyperintensity. Adenomyosis MRI.jpg
Sagittal MRI of a woman's pelvis showing a uterus with adenomyosis in the posterior wall. Gross enlargement of the posterior wall is noted, with many foci of hyperintensity.

Magnetic resonance imaging

Magnetic resonance imaging (MRI) provides slightly better diagnostic capability compared to TVUS, due to the increased ability of MRI to differentiate objectively between different types of soft tissue. [24] This is possible with MRI's higher spatial and contrast resolution. Overall, it is estimated that MRI has a sensitivity of 74% and specificity of 91% for the detection of adenomyosis. [11] Diagnosis through MRI focuses predominately upon investigating the junctional zone. The uterus will have a thickened junctional zone with darker/diminished signal on both T1 and T2 weighted sequences. [24]

Three objective measures of the junctional zone can be used to diagnose adenomyosis. [24]

  1. A thickness of the junctional zone greater than 8–12 mm. Less than 8 mm is normal.
  2. A junctional zone width being greater than 40% of the width of the myometrium.
  3. Variability in the width of the junctional zone being greater than 5 mm.

Interspersed within the thickened, darker signal of the junctional zone, one will often see foci of hyperintensity (bright spots) on the T2 weighted scans representing small cystically dilatated glands or more acute sites of microhemorrhage. [24]

MRI is limited by other factors, but not by calcified uterine fibroids (as is ultrasound). In particular, MRI is better able to differentiate adenomyosis from multiple small uterine fibroids.

Treatment

Adenomyosis can only be cured definitively with surgical removal of the uterus. As adenomyosis is responsive to reproductive hormones, it reasonably abates following menopause when these hormones decrease. For women in their reproductive years, adenomyosis can typically be managed with the goals to provide pain relief, to restrict progression of the process, and to reduce significant menstrual bleeding.

Medications

Hormones and hormone modulators

  • Levonorgestrel-releasing intrauterine devices or hormonal IUDs, such as the Mirena, are an effective treatment for adenomyosis. [31] They reduce symptoms by causing decidualization of the endometrium, reducing or eliminating menstrual flow. [6] Additionally, by helping downregulate estrogen receptors, hormonal IUDs shrink the clusters of endometrial tissue within the myometrium. This leads to reduced menstrual blood flow, helps the uterus contract more properly, and helps to reduce the menstrual pain. The use of hormonal IUDs in patients with adenomyosis have been proven to reduce menstrual bleeding, improve anemia and iron levels, reduce pain, and even result in an improvement of adenomyosis with a smaller uterus on medical imaging. [6] [31] At least in the short term, patients who can tolerate hormonal IUDs for the treatment of adenomyosis result in equivalent improvement of symptoms and better quality-of-life and social well-being as compared to women who undergo a hysterectomy. [6] Hormonal IUDs are particularly well suited for individuals needing effective treatment of their adenomyosis while still maintaining future fertility potential. The most common negative side-effect of hormonal IUDs is irregular menstrual bleeding or spotting. [6]
  • Oral contraceptives  reduce the menstrual pain and bleeding associated with adenomyosis. This may require taking continuous hormone therapy to reducing or eliminating menstrual flow. Oral contraceptives may even lead to short-term regression of adenomyosis.
  • Progesterone  or  Progestins: Progesterone counteracts estrogen and inhibits the growth of endometrial tissue. Such therapy can reduce or eliminate menstruation in a controlled and reversible fashion. Progestins are chemical variants of natural progesterone.
  • Gonadotropin-releasing hormone (GnRH) agonists and danazol have been tried in order to relieve adenomyosis related symptoms and show some effect, but the studies are few, mainly with a retrospective study design and have small sample sizes. [32] Long-time use of GnRH-analogues is often associated with heavy side effects, loss of bone density and increased risk of cardiovascular events, and therefore not feasible for young women. Furthermore, all present treatment options are irrelevant options for women trying to conceive. Exogenous progestogenic treatments have been found to be ineffective. [18] In IVF-settings long down-regulation prior to IVF might have a positive effect on pregnancy rates. [33]

Surgery

Broadly speaking, surgical management of adenomyosis is split into two categories: uterine-sparing and non-uterine-sparing procedures. Uterine-sparing procedures are surgical operations that do not include surgical removal of the uterus. Some uterine-sparing procedures have the benefit of improving fertility or retaining the ability to carry a pregnancy to term. In contrast, some uterine-sparing procedures worsen fertility or even result in complete sterility. The impact of each procedure on a woman's fertility is of particular concern and typically guides the selection. Non-uterine-sparing procedures, by definition, include surgical removal of the uterus and consequently they will all result in complete sterility. [6]

Uterine-sparing procedures

  • Uterine artery embolization (UAE): In this minimally-invasive procedure, doctors intentionally block two large arteries that supply the uterus, called the uterine arteries. This is performed in order to dramatically reduce the blood supply to the uterus. By doing so, there is insufficient blood and thus oxygen present for the adenomyosis to develop and spread.  57-75% of women who undergo UAE for adenomyosis typically report long-term improvement in their menstrual pain and bleeding. However, there is a recurrence rate of symptoms in 35% of women following a UAE. Also, UAE has the risk of causing major complications in 5% of women who undergo the procedure. Major complications include infection, significant bleeding, and needing an additional surgery. UAE has also been shown in some cases to reduce ovarian function. Finally, 26% of women who undergo UAE ultimately end up requiring a hysterectomy. [6]
  • Myometrium or adenomyoma resection: In this procedure, surgeons remove a focal consolidation of adenomyosis known as an adenomyoma. To be successful this procedure requires that the adenomyosis is relatively focally isolated and with a minimal diffuse spread. Unfortunately, adenomyosis is commonly diffuse and the operation is successful only 50% of the time. The procedure is performed with either a laparoscope or hysteroscope. Additionally, it can be a difficult surgery to perform as diffuse adenomyosis physically weakens the myometrium and surgical sutures can tear through the muscle with minimal force. When successful, the procedure significantly improves menstrual pain and bleeding. Additionally, it can result in improved fertility with pregnancy rates as high as 78% in women trying to conceive after the operation with successful delivery occurring in as many as 69% of those pregnancies. On the other hand, there is an increased miscarriage rate (as high as 39% of pregnancies), which is higher than the general population. This is likely due to increased uterine scar tissue formation caused by the surgery. [6]
  • Myometrial electrocoagulation [6]
  • Myometrial reduction [6]
  • MRI-guided focused ultrasound surgery [6]

Endometrial ablation and resection

  • Endometrial ablation techniques are only for people who do not want to bear any children after having the surgery. The techniques either include physical resection and removal of the endometrium through a hysteroscope, or focus on ablating or killing the endometrial layer of the uterus without its immediate removal. Endometrial ablation and resection techniques are most appropriate for shallow adenomyosis. The efficacy of the procedures is reduced if the adenomyosis is too widespread or deep. Furthermore, deep adenomyosis may become trapped behind a scarred region that was ablated, leading to further bleeding and pain. Endometrial resection is also limited to relatively shallow adenomyosis as significant bleeding may result from damage to large arteries that are present 5 mm deep within the myometrium. [6]
    • Non-hysteroscopic procedures: These techniques do not require a hysteroscope, are relatively fast, and many can be performed as an outpatient procedure.
      • High-energy radiofrequency ablation: Using a small expandable mesh placed within the uterus, providers use high-energy radio waves to ablate the endometrium.
      • Thermal balloon: Using a thin expanding balloon placed within the uterus, providers can introduce heated fluid and ablate the endometrium. This procedure has been shown to result in amenorrhea or complete cessation of menstrual bleeding for 12 months in 23% of patients. 16% of patients eventually experience treatment failure with pain or bleeding requiring additional treatments or a hysterectomy. Women older than 45 and those with milder adenomyosis were more likely to experience successful amenorrhea following the procedure. In contrast, women younger than 45, with multiple childbirths, a history of a prior tubal ligation, and/or a history of menstrual pain were more likely to experience treatment failure. [6]
      • Cryo-endometrial ablation (CEA): A form of cryotherapy whereby using a small probe, providers can directly apply sub-zero temperatures within the uterus to freeze and ablate the endometrium.
      • Circulating Hot Water: Heated water directly introduced into the uterus is used to thermally ablate the endometrium.
      • Microwave ablation: Using a small probe introduced into the uterus, a provider uses microwave energy to ablate the endometrium.
    • Hysteroscopic procedures: These techniques all require the use of a hysteroscope to perform.
      • Wire-loop resection: Under direct visualization through a hysteroscope, a wire loop instrument charged with an electric current permits a provider to carefully remove the endometrium in strips.
      • Laser ablation: Under direct visualization through a hysteroscope, lasers are used to vaporize and ablate the endometrium.
      • Rollerball ablation: Under direct visualization through a hysteroscope, a metallic ball on the end of a probe is charged with electricity and rolled across the surface of the endometrium. This has been shown to have a coagulative effect to the depth of 2–3 mm into the myometrium. This destroys the endometrium and the nearby growth of dysfunctional smooth muscle. Deeper adenomyosis escapes this coagulative effect. [6]

Non-uterine-sparing procedures

Hysterectomy, or surgical removal of the uterus, has historically been the primary method of diagnosing and treating adenomyosis. [6] It was especially popular in women who had completed their childbearing or in cases where fertility was not desired. Today, there are many more medical and surgical interventions available. These treatments, such as hormonal therapy and endometrial ablation, have significantly reduced the number of women who require a hysterectomy. That being said, hysterectomies remain as the final treatment option for women in whom the other treatments have failed. [34] Typically viewed as definitive treatment for the bleeding and pelvic pain associated with adenomyosis, a hysterectomy will always result in sterility and cessation of menstrual bleeding. Pelvic pain, on the other hand, can persist after a hysterectomy in as many as 22% of women. [6]

There are many different types of hysterectomy, with varying options existing to removal the fallopian tubes, ovaries, and cervix. Also, the varying types of hysterectomy can be performed by many different surgical techniques.

A hysterectomy can be performed:

  • laparoscopically through small holes in the abdomen
  • robotically in a manner similar to the laparoscopic procedure
  • entirely by route of the vagina with no abdominal incisions
  • through a larger abdominal incision

Variants also exist which combine several of these techniques and surgeries can even change during the operation from one technique to another in response to unforeseen obstacles or individual anatomy considerations. For example, adenomyosis can increase the size of the uterus to such an extent that it physically cannot be removed through the vagina without first being cut into smaller pieces.

Epidemiology

Recent data suggest a prevalence of 20 to 35%. [1]

Prognosis

Adenomyosis is an often progressing condition. It is advocated that adenomyosis poses no increased risk for cancer development. However, both entities could coexist and the endometrial tissue within the myometrium could harbor endometrioid adenocarcinoma, with potentially deep myometrial invasion. [35]

Fertility

Preterm labour and premature rupture of membranes both occur more frequently in women with adenomyosis. [10] [11]

In sub-fertile women who received in-vitro fertilization (IVF), women with adenomyosis were less likely to become pregnant and subsequently more likely to experience a miscarriage. [36] Given this, it is encouraged to screen women for adenomyosis by TVUS or MRI before starting assisted reproduction treatments (ART). [36]

Etymology

The term adenomyosis is derived from the Greek terms adeno- (meaning gland ), myo- (meaning muscle ), and -osis (meaning condition). [37] [38]

See also

Related Research Articles

<span class="mw-page-title-main">Endometrium</span> Inner mucous membrane of the mammalian uterus

The endometrium is the inner epithelial layer, along with its mucous membrane, of the mammalian uterus. It has a basal layer and a functional layer: the basal layer contains stem cells which regenerate the functional layer. The functional layer thickens and then is shed during menstruation in humans and some other mammals, including other apes, Old World monkeys, some species of bat, the elephant shrew and the Cairo spiny mouse. In most other mammals, the endometrium is reabsorbed in the estrous cycle. During pregnancy, the glands and blood vessels in the endometrium further increase in size and number. Vascular spaces fuse and become interconnected, forming the placenta, which supplies oxygen and nutrition to the embryo and fetus. The speculated presence of an endometrial microbiota has been argued against.

<span class="mw-page-title-main">Uterus</span> Female sex organ in mammals

The uterus or womb is the organ in the reproductive system of most female mammals, including humans, that accommodates the embryonic and fetal development of one or more embryos until birth. The uterus is a hormone-responsive sex organ that contains glands in its lining that secrete uterine milk for embryonic nourishment.

<span class="mw-page-title-main">Hysterectomy</span> Surgical removal of the uterus

Hysterectomy is the surgical removal of the uterus and cervix. Supracervical hysterectomy refers to removal of the uterus while the cervix is spared. These procedures may also involve removal of the ovaries (oophorectomy), fallopian tubes (salpingectomy), and other surrounding structures. The term “partial” or “total” hysterectomy are lay-terms that incorrectly describe the addition or omission of oophorectomy at the time of hysterectomy. These procedures are usually performed by a gynecologist. Removal of the uterus renders the patient unable to bear children and has surgical risks as well as long-term effects, so the surgery is normally recommended only when other treatment options are not available or have failed. It is the second most commonly performed gynecological surgical procedure, after cesarean section, in the United States. Nearly 68 percent were performed for conditions such as endometriosis, irregular bleeding, and uterine fibroids. It is expected that the frequency of hysterectomies for non-malignant indications will continue to fall given the development of alternative treatment options.

<span class="mw-page-title-main">Uterine cancer</span> Medical condition

Uterine cancer, also known as womb cancer, includes two types of cancer that develop from the tissues of the uterus. Endometrial cancer forms from the lining of the uterus, and uterine sarcoma forms from the muscles or support tissue of the uterus. Endometrial cancer accounts for approximately 90% of all uterine cancers in the United States. Symptoms of endometrial cancer include changes in vaginal bleeding or pain in the pelvis. Symptoms of uterine sarcoma include unusual vaginal bleeding or a mass in the vagina.

<span class="mw-page-title-main">Endometrial cancer</span> Uterine cancer that is located in tissues lining the uterus

Endometrial cancer is a cancer that arises from the endometrium. It is the result of the abnormal growth of cells that have the ability to invade or spread to other parts of the body. The first sign is most often vaginal bleeding not associated with a menstrual period. Other symptoms include pain with urination, pain during sexual intercourse, or pelvic pain. Endometrial cancer occurs most commonly after menopause.

Heavy menstrual bleeding (HMB), previously known as menorrhagia or hematomunia, is a menstrual period with excessively heavy flow. It is a type of abnormal uterine bleeding (AUB).

Abnormal uterine bleeding (AUB), also known as atypical vaginal bleeding (AVB), is vaginal bleeding from the uterus that is abnormally frequent, lasts excessively long, is heavier than normal, or is irregular. The term dysfunctional uterine bleeding was used when no underlying cause was present. Vaginal bleeding during pregnancy is excluded. Iron deficiency anemia may occur and quality of life may be negatively affected.

<span class="mw-page-title-main">Vaginal bleeding</span> Medical condition

Vaginal bleeding is any expulsion of blood from the vagina. This bleeding may originate from the uterus, vaginal wall, or cervix. Generally, it is either part of a normal menstrual cycle or is caused by hormonal or other problems of the reproductive system, such as abnormal uterine bleeding.

<span class="mw-page-title-main">Endometrial polyp</span> Medical condition

An endometrial polyp or uterine polyp is a mass in the inner lining of the uterus. They may have a large flat base (sessile) or be attached to the uterus by an elongated pedicle (pedunculated). Pedunculated polyps are more common than sessile ones. They range in size from a few millimeters to several centimeters. If pedunculated, they can protrude through the cervix into the vagina. Small blood vessels may be present, particularly in large polyps.

<span class="mw-page-title-main">Uterine fibroid</span> Medical condition with benign tumors of uterus

Uterine fibroids, also known as uterine leiomyomas or fibroids, are benign smooth muscle tumors of the uterus, part of the female reproductive system. Some women with fibroids have no symptoms while others may have painful or heavy periods. If large enough, they may push on the bladder, causing a frequent need to urinate. They may also cause pain during penetrative sex or lower back pain. A woman can have one uterine fibroid or many. It is uncommon but possible that fibroids may make it difficult to become pregnant.

<span class="mw-page-title-main">Uterine artery embolization</span>

Uterine artery embolization is a procedure in which an interventional radiologist uses a catheter to deliver small particles that block the blood supply to the uterine body. The procedure is primarily done for the treatment of uterine fibroids and adenomyosis. Since uterine fibroids are the most common indication, it is also often referred to as uterine fibroid embolization. Compared to surgical treatment for fibroids such as a hysterectomy, in which a woman's uterus is removed, uterine artery embolization may be beneficial in women who wish to retain their uterus. Other reasons for uterine artery embolization are postpartum hemorrhage and uterine arteriovenous malformations.

Intermenstrual bleeding (IMB) is vaginal bleeding at irregular intervals between expected menstrual periods. It may be associated with bleeding with sexual intercourse.

Adenomyoma is a tumor (-oma) including components derived from glands (adeno-) and muscle (-my-). It is a type of complex and mixed tumor, and several variants have been described in the medical literature. Uterine adenomyoma, the localized form of uterine adenomyosis, is a tumor composed of endometrial gland tissue and smooth muscle in the myometrium. Adenomyomas containing endometrial glands are also found outside of the uterus, most commonly on the uterine adnexa but can also develop at distant sites outside of the pelvis. Gallbladder adenomyoma, the localized form of adenomyomatosis, is a polypoid tumor in the gallbladder composed of hyperplastic mucosal epithelium and muscularis propria.

<span class="mw-page-title-main">Endometrial ablation</span> Medical procedure

Endometrial ablation is a surgical procedure that is used to remove (ablate) or destroy the endometrial lining of the uterus. The goal of the procedure is to decrease the amount of blood loss during menstrual periods. Endometrial ablation is most often employed in people with excessive menstrual bleeding, who do not wish to undergo a hysterectomy, following unsuccessful medical therapy.

<span class="mw-page-title-main">Menstrual disorder</span> Medical condition affecting menstrual cycle

A menstrual disorder is characterized as any abnormal condition with regards to a woman's menstrual cycle. There are many different types of menstrual disorders that vary with signs and symptoms, including pain during menstruation, heavy bleeding, or absence of menstruation. Normal variations can occur in menstrual patterns but generally menstrual disorders can also include periods that come sooner than 21 days apart, more than 3 months apart, or last more than 10 days in duration. Variations of the menstrual cycle are mainly caused by the immaturity of the hypothalamic-pituitary-ovarian (HPO) axis, and early detection and management is required in order to minimize the possibility of complications regarding future reproductive ability.

The uterine sarcomas form a group of malignant tumors that arises from the smooth muscle or connective tissue of the uterus. They can be difficult to detect, as symptoms are common to other uterine conditions and no specific screening test has been developed. This presents an issue for treatment, as the cancer spreads quickly.

Uterine clear-cell carcinoma (CC) is a rare form of endometrial cancer with distinct morphological features on pathology; it is aggressive and has high recurrence rate. Like uterine papillary serous carcinoma CC does not develop from endometrial hyperplasia and is not hormone sensitive, rather it arises from an atrophic endometrium. Such lesions belong to the type II endometrial cancers.

<span class="mw-page-title-main">Interstitial pregnancy</span> Medical condition

An interstitial pregnancy is a uterine but ectopic pregnancy; the pregnancy is located outside the uterine cavity in that part of the fallopian tube that penetrates the muscular layer of the uterus. The term cornual pregnancy is sometimes used as a synonym, but remains ambiguous as it is also applied to indicate the presence of a pregnancy located within the cavity in one of the two upper "horns" of a bicornuate uterus. Interstitial pregnancies have a higher mortality than ectopics in general.

The uterus-like mass (ULM) is a tumorlike anatomical entity originally described in the ovary in 1981 and thereafter reported in several locations of the pelvis and abdominal cavity including broad ligament, greater omentum, cervix, small intestine, mesentery and conus medullaris. Basically, it is represented by a miniature uterus comprising a smooth muscle wall lined by endometrium thus outlining a uterus anatomical structure. Some of the reported cases have been associated to urinary tract and internal genitalia malformations whereas others appeared as a solitary finding. The term endomyometriosis has also been applied to this lesion.

Thoracic endometriosis is a rare form of endometriosis where endometrial-like tissue is found in the lung parenchyma and/or the pleura. It can be classified as either pulmonary, or pleural, respectively. Endometriosis is characterized by the presence of tissue similar to the lining of the uterus forming abnormal growths elsewhere in the body. Usually these growths are found in the pelvis, between the rectum and the uterus, the ligaments of the pelvis, the bladder, the ovaries, and the sigmoid colon. The cause is not known. The most common symptom of thoracic endometriosis is chest pain occurring right before or during menstruation. Diagnosis is based on clinical history and examination, augmented with X-ray, CT scan, and magnetic resonance imaging of the chest. Treatment options include surgery and hormones.

References

  1. 1 2 Gunther R, Walker CW (2020). "Adenomyosis". Statpearls. PMID   30969690.
  2. 1 2 R G, C W (2020). "Adenomyosis". StatPearls [Internet]. PMID   30969690.
  3. 1 2 Brosens I, Gordts S, Habiba M, Benagiano G (December 2015). "Uterine Cystic Adenomyosis: A Disease of Younger Women". J Pediatr Adolesc Gynecol. 28 (6): 420–6. doi:10.1016/j.jpag.2014.05.008. PMID   26049940.
  4. 1 2 3 Katz VL (2007). Comprehensive gynecology (5th ed.). Philadelphia PA: Mosby Elsevier.
  5. ↑ Leyendecker, G., Herbertz, M., Kunz, G., Mall, G. (2002). "Endometriosis results from the dislocation of basal endometrium". Hum. Reprod. 17 (10): 2725–2736. doi: 10.1093/humrep/17.10.2725 . PMID   12351554.
  6. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 Struble J, Reid S, Bedaiwy MA (2016). "Adenomyosis: A Clinical Review of a Challenging Gynecologic Condition". Journal of Minimally Invasive Gynecology. 23 (2): 164–185. doi:10.1016/j.jmig.2015.09.018. PMID   26427702.
  7. ↑ Lazzeri L, Di Giovanni A, Exacoustos C, Tosti C, Pinzauti S, Malzoni M, Petraglia F, Zupi E (August 2014). "Preoperative and Postoperative Clinical and Transvaginal Ultrasound Findings of Adenomyosis in Patients With Deep Infiltrating Endometriosis". Reprod Sci. 21 (8): 1027–1033. doi:10.1177/1933719114522520. PMID   24532217. S2CID   24041889.
  8. ↑ "adenomyometritis" at Dorland's Medical Dictionary
  9. ↑ Matalliotakis I, Kourtis A, Panidis D (2003). "Adenomyosis". Obstetrics and Gynecology Clinics of North America. 30 (1): 63–82, viii. doi:10.1016/S0889-8545(02)00053-0. PMID   12699258.
  10. 1 2 Juang CM, Chou P, Yen MS, Twu NF, Horng HC, Hsu WL (2007-02-01). "Adenomyosis and risk of preterm delivery". BJOG: An International Journal of Obstetrics & Gynaecology. 114 (2): 165–169. doi:10.1111/j.1471-0528.2006.01186.x. ISSN   1471-0528. PMID   17169011. S2CID   37765088.
  11. 1 2 3 4 Maheshwari A, Gurunath S, Fatima F, Bhattacharya S (2012). "Adenomyosis and subfertility: A systematic review of prevalence, diagnosis, treatment and fertility outcomes". Human Reproduction Update. 18 (4): 374–392. doi: 10.1093/humupd/dms006 . PMID   22442261.
  12. ↑ Leyendecker G, Kunz G, Kissler S, Wildt L (August 2006). "Adenomyosis and reproduction". Best Pract Res Clin Obstet Gynaecol. 20 (4): 523–46. doi:10.1016/j.bpobgyn.2006.01.008. PMID   16520094.
  13. ↑ Benagiano G, Brosens I, Habiba M (2013). "Structural and molecular features of the endomyometrium in endometriosis and adenomyosis". Human Reproduction Update. 20 (3): 386–402. doi: 10.1093/humupd/dmt052 . ISSN   1355-4786. PMID   24140719.
  14. ↑ Brosens I, Derwig I, Brosens J, Fusi L, Benagiano G, Pijnenborg R (March 2010). "The enigmatic uterine junctional zone: the missing link between reproductive disorders and major obstetrical disorders?". Hum. Reprod. 25 (3): 569–74. doi: 10.1093/humrep/dep474 . PMID   20085913.
  15. ↑ Kitawaki J (August 2006). "Adenomyosis: the pathophysiology of an oestrogen-dependent disease". Best Pract Res Clin Obstet Gynaecol. 20 (4): 493–502. doi:10.1016/j.bpobgyn.2006.01.010. PMID   16564227.
  16. ↑ Kitawaki J, Obayashi H, Ishihara H, Koshiba H, Kusuki I, Kado N, Tsukamoto K, Hasegawa G, Nakamura N, Honjo H (January 2001). "Oestrogen receptor-alpha gene polymorphism is associated with endometriosis, adenomyosis and leiomyomata". Hum. Reprod. 16 (1): 51–55. doi: 10.1093/humrep/16.1.51 . PMID   11139535.
  17. ↑ Ota H, Igarashi S, Hatazawa J, Tanaka T (1998). "Is adenomyosis an immune disease?". Hum. Reprod. Update. 4 (4): 360–7. doi: 10.1093/humupd/4.4.360 . PMID   9825851.
  18. 1 2 Bergeron C, Amant F, Ferenczy A (August 2006). "Pathology and physiopathology of adenomyosis". Best Pract Res Clin Obstet Gynaecol. 20 (4): 511–21. doi:10.1016/j.bpobgyn.2006.01.016. PMID   16563870.
  19. ↑ Nepomnyashchikh LM, Lushnikova EL, Molodykh OP, Pichigina AK (August 2013). "Immunocytochemical analysis of proliferative activity of endometrial and myometrial cell populations in focal and stromal adenomyosis". Bull. Exp. Biol. Med. 155 (4): 512–7. doi:10.1007/s10517-013-2190-5. PMID   24143380. S2CID   478916.
  20. ↑ Leyendecker G, Wildt L, Mall G (October 2009). "The pathophysiology of endometriosis and adenomyosis: tissue injury and repair". Arch. Gynecol. Obstet. 280 (4): 529–38. doi:10.1007/s00404-009-1191-0. PMC   2730449 . PMID   19644696.
  21. 1 2 Leyendecker G, Bilgicyildirim A, Inacker M, Stalf T, Huppert P, Mall G, Böttcher B, Wildt L (April 2015). "Adenomyosis and endometriosis. Re-visiting their association and further insights into the mechanisms of auto-traumatisation. An MRI study". Arch. Gynecol. Obstet. 291 (4): 917–32. doi:10.1007/s00404-014-3437-8. PMC   4355446 . PMID   25241270.
  22. ↑ Koike H, Egawa H, Ohtsuka T, Yamaguchi M, Ikenoue T, Mori N (June 1992). "Correlation between dysmenorrheic severity and prostaglandin production in women with endometriosis". Prostaglandins, Leukotrienes and Essential Fatty Acids. 46 (2): 133–137. doi:10.1016/0952-3278(92)90219-9. ISSN   0952-3278. PMID   1502250.
  23. 1 2 3 Nucci MR (3 February 2020). Gynecologic pathology: a volume in the series Foundations in diagnostic pathology (Second ed.). Elsevier. p. 489. ISBN   978-0-323-35909-2.
  24. 1 2 3 4 5 6 7 8 9 Exacoustos C, Manganaro L, Zupi E (2014). "Imaging for the evaluation of endometriosis and adenomyosis" (PDF). Best Practice & Research Clinical Obstetrics & Gynaecology. 28 (5): 655–681. doi:10.1016/j.bpobgyn.2014.04.010. hdl: 2108/137400 . PMID   24861247.
  25. ↑ Torloni MR, Vedmedovska N, Merialdi M, Betrán AP, Allen T, González R, Platt LD (2009-05-01). "Safety of ultrasonography in pregnancy: WHO systematic review of the literature and meta-analysis". Ultrasound in Obstetrics and Gynecology. 33 (5): 599–608. doi: 10.1002/uog.6328 . ISSN   1469-0705. PMID   19291813. S2CID   9986561.
  26. ↑ Van den Bosch T, Dueholm M, Leone FP, Valentin L, Rasmussen CK, Votino A, Van Schoubroeck D, Landolfo C, Installé AJ, Guerriero S, Exacoustos C, Gordts S, Benacerraf B, D'Hooghe T, De Moor B (September 2015). "Terms, definitions and measurements to describe sonographic features of myometrium and uterine masses: a consensus opinion from the Morphological Uterus Sonographic Assessment (MUSA) group". Ultrasound in Obstetrics & Gynecology. 46 (3): 284–298. doi:10.1002/uog.14806. hdl: 2108/137794 . ISSN   1469-0705. PMID   25652685. S2CID   226070.
  27. ↑ Harmsen MJ, Van den Bosch T, de Leeuw RA, Dueholm M, Exacoustos C, Valentin L, Hehenkamp WJ, Groenman F, De Bruyn C, Rasmussen C, Lazzeri L, Jokubkiene L, Jurkovic D, Naftalin J, Tellum T (July 2022). "Consensus on revised definitions of Morphological Uterus Sonographic Assessment (MUSA) features of adenomyosis: results of modified Delphi procedure". Ultrasound in Obstetrics & Gynecology. 60 (1): 118–131. doi:10.1002/uog.24786. ISSN   1469-0705. PMC   9328356 . PMID   34587658.
  28. ↑ Dartmouth K (2014-08-01). "A systematic review with meta-analysis: the common sonographic characteristics of adenomyosis". Ultrasound. 22 (3): 148–157. doi:10.1177/1742271X14528837. ISSN   1742-271X. PMC   4760530 . PMID   27433212.
  29. ↑ Sharma K (2015). "Role of 3D Ultrasound and Doppler in Differentiating Clinically Suspected Cases of Leiomyoma and Adenomyosis of Uterus". Journal of Clinical and Diagnostic Research. 9 (4): QC08–12. doi:10.7860/jcdr/2015/12240.5846. PMC   4437118 . PMID   26023602.
  30. ↑ Harmsen MJ, Trommelen LM, de Leeuw RA, Tellum T, Juffermans LJ, Griffioen AW, Thomassin-Naggara I, Van den Bosch T, Huirne Ja (July 2023). "Uterine junctional zone and adenomyosis: comparison of MRI, transvaginal ultrasound and histology". Ultrasound in Obstetrics & Gynecology. 62 (1): 42–60. doi: 10.1002/uog.26117 . ISSN   1469-0705. PMID   36370446. S2CID   253498672.
  31. 1 2 Bragheto A.M., et al. (2007). "Effectiveness of the levonorgestrel-releasing intrauterine system in the treatment of adenomyosis diagnosed and monitored by magnetic resonance imaging". Contraception. 76 (3): 195–9. doi:10.1016/j.contraception.2007.05.091. PMID   17707716.
  32. ↑ Maheshwari A, Gurunath S, Fatima F, Bhattacharya S (July 2012). "Adenomyosis and subfertility: a systematic review of prevalence, diagnosis, treatment and fertility outcomes". Hum. Reprod. Update. 18 (4): 374–92. doi: 10.1093/humupd/dms006 . PMID   22442261.
  33. ↑ Niu Z, Chen Q, Sun Y, Feng Y (December 2013). "Long-term pituitary downregulation before frozen embryo transfer could improve pregnancy outcomes in women with adenomyosis". Gynecol. Endocrinol. 29 (12): 1026–30. doi:10.3109/09513590.2013.824960. PMID   24006906. S2CID   39831081.
  34. ↑ , Levgur M (2007). "Therapeutic options for adenomyosis: a review". Archives of Gynecology and Obstetrics. 276 (1): 1–15. doi:10.1007/S00404-006-0299-8. PMID   17186255. S2CID   228334.
  35. ↑ Ismiil N, Rasty G, Ghorab Z, et al. (August 2007). "Adenomyosis involved by endometrial adenocarcinoma is a significant risk factor for deep myometrial invasion". Ann Diagn Pathol. 11 (4): 252–7. doi:10.1016/j.anndiagpath.2006.08.011. PMID   17630108.
  36. 1 2 Vercellini P, Consonni D, Dridi D, Bracco B, Frattaruolo MP, Somigliana E (2014-05-01). "Uterine adenomyosis and in vitro fertilization outcome: a systematic review and meta-analysis". Human Reproduction. 29 (5): 964–977. doi: 10.1093/humrep/deu041 . ISSN   0268-1161. PMID   24622619.
  37. ↑ Stratopoulou CA, Donnez J, Dolmans MM (2021). "Origin and Pathogenic Mechanisms of Uterine Adenomyosis: What Is Known So Far". Reproductive Sciences. 28 (8): 2087–2097. doi:10.1007/s43032-020-00361-w. ISSN   1933-7191.
  38. ↑ "-OSIS Definition & Meaning". Dictionary.com. 2023-07-04. Retrieved 2024-07-17.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.